TransMedics Group Inc. (TMDX)
Bronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Investors to Inquire about Securities Investigation
NEW YORK CITY, NY / ACCESSWIRE / January 15, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
TransMedics Group, Inc. Is Being Investigated For Securities Law Violations And Impacted Shareholders Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / January 14, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TransMedics Group, Inc. ("TransMedics" or "the Company") (NASDAQ:TMDX). Investors who purchased TransMedics securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TMDX.
TransMedics Group ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses
BOSTON, MA / ACCESSWIRE / January 13, 2025 / Block & Leviton is investigating TransMedics Group, Inc. (Nasdaq:TMDX) for potential securities law violations. Investors who have lost money in their TransMedics Group, Inc. investment should contact the firm to learn more about how they might recover those losses.
TransMedics Stock Is Worth $0 According to This Short-Seller. Here's Why I'm Not Selling.
In this video, I will talk about TransMedics (TMDX -5.16%) and the recent short-seller report. Watch the short video to learn more, consider subscribing, and click the special offer link below.
Kehoe Law Firm, P.C. Securities Investigation on Behalf of Investors of TransMedics Group Stock Following Critical Report - NASDAQ: TMDX
PHILADELPHIA, PA / ACCESSWIRE / January 10, 2025 / Kehoe Law Firm, P.C. is investigating potential securities class action claims on behalf of investors of TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ:TMDX) stock after the Company's stock price dropped significantly during intraday trading today.
Why TransMedics Group Stock Is Tanking Today
Shares of TransMedics Group (TMDX -12.34%) were tanking 14.3% lower as of 10:46 a.m. ET on Friday.
Why Transmedics Plunged in December
Shares of Transmedics (TMDX 9.47%) fell 28.1% in December, according to data from S&P Global Market Intelligence.
Buying The Dip: How TransMedics Is Set To Soar In A Potential $23 Billion Market
Buying The Dip: How TransMedics Is Set To Soar In A Potential $23 Billion Market
1 Super Growth Stock Down 63% to Buy Hand Over Fist in 2025
Leading organ transplant technology provider TransMedics (TMDX 3.90%) increased sales by more than 100% in 10 straight quarters from early 2022 to mid-2024. However, after delivering revenue growth of "only" 64% in its latest quarter -- while lowering guidance for a 35% increase in the upcoming fourth quarter -- the company has seen its stock plummet roughly 63% from its highs.
Breaking Into Healthcare: Why TransMedics Is My Bold First Move
TransMedics is transforming organ transplants with advanced technology and integrated logistics. Strong market demand and expanding adoption support long-term growth potential despite the recent top-line deceleration. Following the recent nosedive, the stock's current valuation offers an attractive entry point for a market leader in a critical industry.
TransMedics Stock Plunges 57.5% in Three Months: What's Next?
TMDX is enhancing its current focus on making meaningful progress across each of its growth initiatives. However, macro challenges are likely to hurt its performance.
